ESEdgar Selzer

Edgar Selzer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Edgar Selzer has a total of 23 co-authors. Here are the top co-authors by number of shared publications:

  • Burkhard Jansen

    Department of Clinical Pharmacology 18–20, Section of Experimental Oncology and Molecular Pharmacology, University Hospital Vienna, Vienna, Austria

    2 shared publications
  • Hubert Pehamberger

    Department of Dermatology, Division of General Dermatology, University Hospital Vienna, Vienna, Austria

    2 shared publications
  • Trevor Lucas

    Department for Cell and Developmental Biology, Center for Anatomy and Cell Biology, Medical University of Vienna, Vienna, Austria

    2 shared publications
  • Volker Wacheck

    Department of Clinical Pharmacology 18–20, Section of Experimental Oncology and Molecular Pharmacology, University Hospital Vienna, Vienna, Austria

    2 shared publications
  • Werner Schlegel

    2 shared publications
  • B. Jansen

    1 shared publication

Latest Publications

  • Open Access

    Betulinic Acid-induced Mcl-1 Expression in Human Melanoma — Mode of Action and Functional Significance

    by Edgar Selzer, Christiane Thallinger, Christoph Hoeller, Philipp Oberkleiner, Volker Wacheck, Hubert Pehamberger, Burkhard Jansen

    Currently there is no information on the regulation of expression and physiological role of the anti-apoptotic protein Mcl-1 in cells of the melanocytic lineage. This study investigates the regulation and expression of Mcl-1 in human melanoma cells, which was recently found to be induced by betulinic acid, a compound with anti-melanoma and apoptosis-inducing potential. Mcl-1 phosphorthioate anti-sense oligonucleotides were used to investigate the effect of downregulating the expression of Mcl-1. Regulation of Mcl-1 expression was analyzed with the specific PI3-kinase inhibitors LY294002 and wortmannin and the inhibitor of MAP-kinase activation, PD98059. Western blot analysis was performed with anti ERK1/2, Mcl-1, Bak, Bcl-x and Bax antibodies. Activation status of PI-3 kinase and MAP-kinase pathways was investigated using phospho-Akt and phosphorylation-state independent Akt as well as phospho-MAP kinase, phospho-MEK and phospho-GSK-3α/β antibodies. Upregulation of Mcl-1 in human melanoma cells by betulinic acid is mediated via a signal-transduction pathway that is inhibited by LY294002 and wortmannin. Betulinic acid-induced phosphorylation and activation of the Akt protein kinase was inhibited by LY294002. The inhibitor PD98059 reduced expression levels of Mcl-1 in melanoma cells and this effect was counteracted by betulinic acid. Downregulation of Mcl-1 by antisense oligodeoxynucleotides in combination with betulinic treatment led to a synergistic effect regarding growth inhibition. These results suggest that in human melanoma cells Mcl-1 is (i) of functional relevance for survival and (ii) subject to dual regulation by the MAP-kinase pathway and a pathway involving protein kinase B/Akt, the latter of which is modulated in response to betulinic acid. This study provides an experimental foundation for future therapeutic strategies using anti-Mcl-1 antisense oligonucleotides in human melanoma.


  • Protein kinase C isoforms in normal and transformed cells of the melanocytic lineage

    by E. Selzer, I. Okamoto, T. Lucas, R. Kodym, H. Pehamberger, B. Jansen

    Enzymes belonging to the protein kinase C (PKC) family represent one of the major mediators of signal transduction in melanocytes. To identify PKC isoforms that may be associated with the process of malignant transformation and metastasis, we investigated the expression pattern of 11 different PKC isoforms (α, βI, βII, γ, δ, ∊, η, θ, ς, λ and ι) in melanoma lymph node metastases, in cell lines established from these metastases, in primary cell cultures from normal melanocytes, and in permanent cell lines established from spontaneously transformed melanocytes. PKC α, βI, βII, δ, ∊, η, ζ, λ and ι were found to be expressed in total lysates from melanoma metastases. In permanent cell lines established from these metastases, the expression levels of PKC βI, βII, δ, ∊ and η were lower or undetectable when compared with initial expression in tumour lysates. In normal primary melanocyte cultures, the PKC isoforms βII, δ, ∊, η and ι were undetectable. PKC γ and θ isoforms were undetectable in all melanocytic cell types examined. PKC ι was the only isoform exclusively detected in tumour lysates, in spontaneously transformed melanoma cells and melanoma cell lines, but not in normal melanocytes, and may therefore be associated with the transformed phenotype in human melanoma in vitro and in vivo.


    • 1 April 2002
      • Vol. 62  (7) , 2098-103

    The melanocyte-specific isoform of the microphthalmia transcription factor affects the phenotype of human melanoma.

    by Edgar Selzer, Volker Wacheck, Trevor Lucas, Elisabeth Heere-Ress, Min Wu, Katherine N Weilbaecher, Werner Schlegel, Peter Valent, Fritz Wrba, Hubert Pehamberger, et al.

    The microphthalmia transcription factor MITF plays a pivotal role in the development and differentiation of melanocytes. The purpose of this work was to investigate the expression and function of the melanocyte-specific isoform MITF-M in human melanoma. We found that MITF-M is repressed in 8 of 14 established melanoma cell lines tested. Transfection of MITF-M into a melanoma cell line (518A2) lacking the M-isoform and into a permanent cell line established from normal melanocytes (NMel-II) resulted in slower tumor growth in a severe combined immunodeficient-mouse xenotransplantation model. The growth difference between vector control-transfected tumors derived from the NMel-II cell line (mean tumor weight +/- SD, 3.2 g +/- 1.13) and MITF-M (+) transfectants (mean tumor weight +/- SD, 1.1 g +/- 0.49) was significant (P = 0.018). The mean tumor weight of control-transfected 518A2 tumors was 0.99 g +/- 0.22 and of MITF-M (+) transfectants, 0.69 g +/- 0.32. The difference in growth between 518A2 controls and the MITF-M (+) transfectants was clear, however it did not reach statistical significance (P = 0.08). In addition to the growth-inhibitory effects, MITF-M expression led to a change in the histopathological appearance of tumors from epitheloid toward a spindle-cell type in vivo. These results indicate a role for the MITF-M isoform in the in vivo growth control and the phenotype of human melanoma. In conclusion, MITF-M may qualify as a marker capable of identifying subgroups of melanoma patients with different tumor biology and prognosis.


  • Effects of Betulinic Acid Alone and in Combination with Irradiation in Human Melanoma Cells

    by Edgar Selzer, Emilio Pimentel, Volker Wacheck, Werner Schlegel, Hubert Pehamberger, Burkhard Jansen, Reinhard Kodym